1
|
Jairath V, Zou G, Wang Z, Adsul S, Colombel JF, D'Haens GR, Freire M, Moran GW, Peyrin-Biroulet L, Sandborn WJ, Sebastian S, Travis S, Vermeire S, Radulescu G, Sigler J, Hanžel J, Ma C, Sedano R, McFarlane SC, Arya N, Beaton M, Bossuyt P, Danese S, Green D, Harlan W, Horynski M, Klopocka M, Petroniene R, Silverberg MS, Wolanski L, Feagan BG. Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial. BMJ Open Gastroenterol 2024; 11:e001218. [PMID: 38336367 PMCID: PMC10870790 DOI: 10.1136/bmjgast-2023-001218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/25/2023] [Accepted: 12/06/2023] [Indexed: 02/12/2024] Open
Abstract
INTRODUCTION Symptoms, endoscopy and histology have been proposed as therapeutic targets in ulcerative colitis (UC). Observational studies suggest that the achievement of histologic remission may be associated with a lower risk of complications, compared with the achievement of endoscopic remission alone. The actiVE ulcerative colitis, a RanDomIsed Controlled Trial (VERDICT) aims to determine the optimal treatment target in patients with UC. METHODS AND ANALYSIS In this multicentre, prospective randomised study, 660 patients with moderate to severe UC (Mayo rectal bleeding subscore [RBS] ≥1; Mayo endoscopic score [MES] ≥2) are randomly assigned to three treatment targets: corticosteroid-free symptomatic remission (Mayo RBS=0) (group 1); corticosteroid-free endoscopic remission (MES ≤1) and symptomatic remission (group 2); or corticosteroid-free histologic remission (Geboes score <2B.0), endoscopic remission and symptomatic remission (group 3). Treatment is escalated using vedolizumab according to a treatment algorithm that is dependent on the patient's baseline UC therapy until the target is achieved at weeks 16, 32 or 48. The primary outcome, the time from target achievement to a UC-related complication, will be compared between groups 1 and 3 using a Cox proportional hazards model. ETHICS AND DISSEMINATION The study was approved by ethics committees at the country level or at individual sites as per individual country requirements. A full list of ethics committees is available on request. Study results will be disseminated in peer-reviewed journals and at scientific meetings. TRIAL REGISTRATION NUMBER EudraCT: 2019-002485-12; NCT04259138.
Collapse
Affiliation(s)
- Vipul Jairath
- Department of Medicine, Division of Gastroenterology; Department of Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, Canada
- Alimentiv Inc, London, Ontario, Canada
| | - Guangyong Zou
- Alimentiv Inc, London, Ontario, Canada
- Department of Epidemiology and Biostatistics; Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada
| | | | - Shashi Adsul
- Takeda Pharmaceuticals, Cambridge, Massachusetts, USA
| | - Jean-Frederic Colombel
- Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Geert R D'Haens
- Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam, The Netherlands
| | | | - Gordon W Moran
- Nottingham Digestive Diseases Biomedical Research Centre, University of Nottingham, Nottingham, UK
- NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - Laurent Peyrin-Biroulet
- INSERM, NGERE, University of Lorraine, Nancy, France
- Department of Gastroenterology; INFINY Institute; FHU-CURE, Nancy University Hospital, Nancy, France
| | - William J Sandborn
- Division of Gastroenterology, University of California San Diego, La Jolla, California, USA
| | | | - Simon Travis
- Kennedy Institute and Biomedical Research Centre, University of Oxford, Oxford, UK
| | - Séverine Vermeire
- Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
| | | | | | - Jurij Hanžel
- Alimentiv Inc, London, Ontario, Canada
- Department of Gastroenterology, University of Ljubljana, Ljubljana, Slovenia
| | - Christopher Ma
- Alimentiv Inc, London, Ontario, Canada
- Division of Gastroenterology & Hepatology, Cumming School of Medicine; Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Rocio Sedano
- Alimentiv Inc, London, Ontario, Canada
- Department of Medicine, Division of Gastroenterology, University of Western Ontario, London, Ontario, Canada
| | | | - Naveen Arya
- ABP Research Services Corp, Oakville, Ontario, Canada
| | - Melanie Beaton
- Department of Medicine, Division of Gastroenterology, University of Western Ontario, London, Ontario, Canada
| | - Peter Bossuyt
- Imelda GI Clinical Research Center, Imelda Hospital, Bonheiden, Belgium
| | - Silvio Danese
- Gastroenterology and Gastrointestinal Endoscopy Unit, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
| | - Daniel Green
- Department of Gastroenterology, Taunton Surgical Centre, Oshawa, Ontario, Canada
| | - William Harlan
- Asheville Gastroenterology Associates, Asheville, North Carolina, USA
| | | | - Maria Klopocka
- Department of Gastroenterology and Nutritional Disorders, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
- Gastroenterology Clinic, Dr. Jana Biziel University Hospital n 2 in Bydgoszcz, Bydgoszcz, Poland
| | | | - Mark S Silverberg
- Toronto Immune and Digestive Health Institute, Toronto, Ontario, Canada
| | - Lukasz Wolanski
- Gastroenterological Department, Samodzielny Publiczny Zakład Opieki Zdrowotnej w Łęcznej, Łęcznej, Poland
| | - Brian G Feagan
- Department of Medicine, Division of Gastroenterology; Department of Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, Canada
- Alimentiv Inc, London, Ontario, Canada
| |
Collapse
|
2
|
Ma C, Singh S, Jairath V, Radulescu G, Ho SKM, Choi MY. Food Insecurity Negatively Impacts Gluten Avoidance and Nutritional Intake in Patients With Celiac Disease. J Clin Gastroenterol 2022; 56:863-868. [PMID: 34802022 DOI: 10.1097/mcg.0000000000001646] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/24/2021] [Accepted: 10/19/2021] [Indexed: 12/10/2022]
Abstract
BACKGROUND Food insecurity is a major public health challenge. For patients with celiac disease (CeD), food insecurity may be particularly detrimental as it threatens the cornerstone of their treatment: adoption of a gluten-free diet (GFD). We aimed to characterize the prevalence of food insecurity in patients with CeD and evaluate its impact on GFD adoption and nutritional intake. METHODS We analyzed data from patients with CeD participating in the US National Health and Nutrition Examination Survey (NHANES) from 2009 to 2014. Food insecurity was defined using the US Department of Agriculture 18-Item Standard Food Security Survey Module. Survey-weighted logistic regression was used to assess differences in demographic characteristics of CeD patients living with food insecurity and the impact of food security on GFD adoption. Multivariable survey-weighted linear regression was used to evaluate the effect of food insecurity on nutritional intake of macronutrients and micronutrients. RESULTS Overall, 15.9% (95% confidence interval: 10.6%, 23.1%) of patients with CeD in the United States [weighted N=2.9 million (95% confidence interval: 2.2, 3.5 million)] are food insecure. Food insecure patients with CeD were disproportionately younger, poorly educated, nonwhite, living in poverty, and were significantly less likely to adopt a GFD (24.1% vs. 67.9%, P =0.02). Food insecurity was associated with significantly lower consumption of protein, carbohydrates, fat, and most vitamins and minerals. CONCLUSIONS One in 6 patients with CeD are food insecure, negatively impacting GFD adoption and the ability to meet recommended daily intake of most micronutrients. Less than one quarter of food insecure CeD patients adhere to a GFD.
Collapse
Affiliation(s)
- Christopher Ma
- Division of Gastroenterology & Hepatology, Department of Medicine, University of Calgary
- Departments of Community Health Sciences, Cumming School of Medicine, University of Calgary
- Alimentiv Inc. (formerly Robarts Clinical Trials Inc.)
| | - Siddharth Singh
- Division of Gastroenterology, University of California San Diego, La Jolla, CA
| | - Vipul Jairath
- Alimentiv Inc. (formerly Robarts Clinical Trials Inc.)
- Division of Gastroenterology
- Department of Epidemiology and Biostatistics, Western University, London, ON, Canada
| | | | | | - May Y Choi
- Division of Rheumatology, McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, AB
| |
Collapse
|
3
|
Michel-Sendis F, Gauld I, Martinez J, Alejano C, Bossant M, Boulanger D, Cabellos O, Chrapciak V, Conde J, Fast I, Gren M, Govers K, Gysemans M, Hannstein V, Havlůj F, Hennebach M, Hordosy G, Ilas G, Kilger R, Mills R, Mountford D, Ortego P, Radulescu G, Rahimi M, Ranta-Aho A, Rantamäki K, Ruprecht B, Soppera N, Stuke M, Suyama K, Tittelbach S, Tore C, Winckel SV, Vasiliev A, Watanabe T, Yamamoto T, Yamamoto T. SFCOMPO-2.0: An OECD NEA database of spent nuclear fuel isotopic assays, reactor design specifications, and operating data. ANN NUCL ENERGY 2017. [DOI: 10.1016/j.anucene.2017.07.022] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
4
|
Lefebvre RA, Miller P, Scaglione JM, Banerjee K, Peterson JL, Radulescu G, Robb KR, Thompson AB, Liljenfeldt H, Lefebvre JP. Development of Streamlined Nuclear Safety Analysis Tool for Spent Nuclear Fuel Applications. NUCL TECHNOL 2017. [DOI: 10.1080/00295450.2017.1314747] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- R. A. Lefebvre
- Oak Ridge National Laboratory, Reactor and Nuclear Systems Division, P.O. Box 2008, Bldg. 5700, Oak Ridge, Tennessee 37831-6170
| | - P. Miller
- Oak Ridge National Laboratory, Reactor and Nuclear Systems Division, P.O. Box 2008, Bldg. 5700, Oak Ridge, Tennessee 37831-6170
| | - J. M. Scaglione
- Oak Ridge National Laboratory, Reactor and Nuclear Systems Division, P.O. Box 2008, Bldg. 5700, Oak Ridge, Tennessee 37831-6170
| | - K. Banerjee
- Oak Ridge National Laboratory, Reactor and Nuclear Systems Division, P.O. Box 2008, Bldg. 5700, Oak Ridge, Tennessee 37831-6170
| | - J. L. Peterson
- Oak Ridge National Laboratory, Reactor and Nuclear Systems Division, P.O. Box 2008, Bldg. 5700, Oak Ridge, Tennessee 37831-6170
| | - G. Radulescu
- Oak Ridge National Laboratory, Reactor and Nuclear Systems Division, P.O. Box 2008, Bldg. 5700, Oak Ridge, Tennessee 37831-6170
| | - K. R. Robb
- Oak Ridge National Laboratory, Reactor and Nuclear Systems Division, P.O. Box 2008, Bldg. 5700, Oak Ridge, Tennessee 37831-6170
| | - A. B. Thompson
- Oak Ridge National Laboratory, Reactor and Nuclear Systems Division, P.O. Box 2008, Bldg. 5700, Oak Ridge, Tennessee 37831-6170
| | - H. Liljenfeldt
- Oak Ridge National Laboratory, Reactor and Nuclear Systems Division, P.O. Box 2008, Bldg. 5700, Oak Ridge, Tennessee 37831-6170
| | - J. P. Lefebvre
- Oak Ridge National Laboratory, Reactor and Nuclear Systems Division, P.O. Box 2008, Bldg. 5700, Oak Ridge, Tennessee 37831-6170
| |
Collapse
|